Bluejay Diagnostics Q2 update: SYMON-II enrollment starts, 510(k) target 2027

Bluejay Diagnostics, Inc.

SYMON-II pivotal trial enrollment began; aims to validate IL-6 for 28-day mortality in ICU patients.
Raised $3.85M in April 2025 warrant inducement financing; anticipates more capital through 2027.
Amended Toray license extends cartridge manufacturing timeline to October 2026.
SanyoSeiko engaged as CMO for Symphony analyzer; cartridge redevelopment via FDA-registered CMO.
No detailed financial results disclosed; company pre-revenue with clinical and operational progress.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.